LONDON (Reuters) - Swiss group Novartis has stepped up its challenge to GlaxoSmithKline's traditional domination of the lung drug market, stealing the limelight with clinical data at a top medical meeting.https://mf.feeds.reuters.com/c/871/f/...3103d54/mf.gif
https://da.feedsportal.com/r/14437092...3103d54/a2.imghttps://pi.feedsportal.com/r/14437092...103d54/a2t.img
More...
